Can a wrong word make a drug ad or promotional piece misleading?

It can. The FDA's September 2025 action on prescription drug ads focused on fair balance and on serious risks that aren't clearly presented. A correctly spelled wrong word in a risk line can change what that line says about a risk, so promotional copy needs a read for meaning, not only a claims check.

This page is general information, not legal or regulatory advice.

What the FDA said in September 2025

In a September 2025 news release, the FDA and the Department of Health and Human Services announced reforms to rein in misleading direct-to-consumer drug ads. The FDA said it was sending letters warning companies to remove misleading ads, and that it was starting rulemaking to close what it called the adequate provision loophole for broadcast and digital ads.

The FDA's letter to industry said the FDA is concerned patients are not seeing a fair balance of the information regarding a drug product, and that this concern is magnified when serious risks are not clearly presented, or the information is too difficult for seniors to read or hear. It directed companies to remove any noncompliant advertising and bring all promotional communications into compliance.

Fair balance in plain terms

The FDA's advertising regulation, 21 CFR 202.1, says a prescription drug ad's brief summary is false or misleading if it fails to present a fair balance between information on side effects and contraindications and information on effectiveness.

The same regulation says brochures, mailing pieces, detailing pieces, letters, exhibits, literature and similar pieces describing a drug, supplied by or on behalf of the manufacturer, packer or distributor, are labeling (21 CFR 202.1(l)(2)). Ads in journals, magazines and newspapers, and broadcast ads, are covered as advertisements (21 CFR 202.1(l)(1)).

How one word can shift a risk line

Our view: fair balance is judged on the words a reader sees. A word that names a milder or different risk than the approved text changes the balance without changing a single claim.

Made-up example: a risk line in a patient brochure should warn about "hypoglycemia" but prints "hyperglycemia". The reader is told to watch for the opposite problem, and the claims elsewhere on the piece are untouched.

Why spellcheck misses it

Both words are real medical terms, spelled correctly. Spellcheck passes them, and a claims review focused on whether benefits are supported can pass them too.

What to check next

Practice advice:

• Read each risk and side-effect line in the promotional piece against the approved labeling for meaning.
• Check that risk lines are as specific and as prominent as the approved text, not softened by a word swap.
• Read broadcast and video scripts aloud, since that's how the audience meets them.
• Use a second reader for risk lines. See the second-reader checklist.

This is our reading of public guidance, not legal or regulatory advice.

Sources

• FDA: FDA Launches Crackdown on Deceptive Drug Advertising (news release)
• FDA: Letter to industry on direct-to-consumer advertising
• eCFR: 21 CFR 202.1

Last reviewed: October 18, 2026

More on contextual errors in FDA DailyMed labels.

Questions about wording on your own labels? Talk to us.

We scan freshly published FDA DailyMed labels every day and pull out these high-stakes wrong words.

Every Tuesday and Friday, a new case like this lands in your inbox if you subscribe.

What did the FDA's September 2025 action on drug ads target?

Misleading direct-to-consumer ads, especially where serious risks aren't clearly presented. The FDA directed companies to remove noncompliant ads and bring promotional communications into compliance.

Can a wrong word make a drug ad misleading?

It can if it changes how a risk or benefit reads. Fair balance depends on the actual words on the page or screen.

Is promotional material labeling?

Many printed and audiovisual promotional pieces supplied by or for the manufacturer count as labeling in 21 CFR 202.1(l)(2). Broadcast and print ads are covered as advertisements.

Does promotional review check wording for meaning?

Not always. Practice advice: add a read for meaning on each risk line, against the approved labeling, alongside the claims check.

Is the FDA changing the rules for broadcast drug ads?

In September 2025, the FDA said it was starting rulemaking on what it called the adequate provision loophole for broadcast and digital ads. As of October 18, 2026, we found no proposed rule on it in the Federal Register.